![JCM | Free Full-Text | The Prognostic Model of Pre-Treatment Complete Blood Count (CBC) for Recurrence in Early Cervical Cancer JCM | Free Full-Text | The Prognostic Model of Pre-Treatment Complete Blood Count (CBC) for Recurrence in Early Cervical Cancer](https://www.mdpi.com/jcm/jcm-09-02960/article_deploy/html/images/jcm-09-02960-g001.png)
JCM | Free Full-Text | The Prognostic Model of Pre-Treatment Complete Blood Count (CBC) for Recurrence in Early Cervical Cancer
Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics | PLOS ONE
![ASCO GU 2023: FORMULA-509: A Multicenter Randomized Trial of Post-Operative Salvage Radiotherapy and 6 Months of GnRH Agonist with or Without Abiraterone Acetate/prednisone and Apalutamide Post-Radical Prostatectomy ASCO GU 2023: FORMULA-509: A Multicenter Randomized Trial of Post-Operative Salvage Radiotherapy and 6 Months of GnRH Agonist with or Without Abiraterone Acetate/prednisone and Apalutamide Post-Radical Prostatectomy](https://www.urotoday.com/images/com-doc-importer/103-asco-gu-2023/asco-gu-2023-formula-509-a-multicenter-randomized-trial-of-post-operative-salvage-radiotherapy-and-6-months-of-gnrh-agonist-with-or-without-abiraterone-acetate-prednisone-and-apalutamide-post-radical-prostatectomy/image-0.jpg)
ASCO GU 2023: FORMULA-509: A Multicenter Randomized Trial of Post-Operative Salvage Radiotherapy and 6 Months of GnRH Agonist with or Without Abiraterone Acetate/prednisone and Apalutamide Post-Radical Prostatectomy
![Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials - ScienceDirect Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0959804919307488-gr1.jpg)
Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials - ScienceDirect
![On Biostatistics and Clinical Trials: Understanding the endpoints in oncology: overall survival, progression free survival, hazard ratio, censored value On Biostatistics and Clinical Trials: Understanding the endpoints in oncology: overall survival, progression free survival, hazard ratio, censored value](http://1.bp.blogspot.com/-kUQ4plu5Z10/VetKmGP3SNI/AAAAAAAAAk0/EcsbkS6qlFQ/w1200-h630-p-k-no-nu/image002.gif)
On Biostatistics and Clinical Trials: Understanding the endpoints in oncology: overall survival, progression free survival, hazard ratio, censored value
![A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer - Annals of Oncology A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer - Annals of Oncology](https://www.annalsofoncology.org/cms/asset/80addcfc-5a3d-41a1-92be-1d7b6a968bbe/gr1.jpg)
A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer - Annals of Oncology
![A retrospective analysis of changes in distant and breast cancer related disease-free survival events in adjuvant breast cancer trials over time | Scientific Reports A retrospective analysis of changes in distant and breast cancer related disease-free survival events in adjuvant breast cancer trials over time | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-022-09949-5/MediaObjects/41598_2022_9949_Fig1_HTML.png)
A retrospective analysis of changes in distant and breast cancer related disease-free survival events in adjuvant breast cancer trials over time | Scientific Reports
![Estimating progression-free survival in patients with glioblastoma using routinely collected data | SpringerLink Estimating progression-free survival in patients with glioblastoma using routinely collected data | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11060-017-2619-1/MediaObjects/11060_2017_2619_Fig1_HTML.gif)
Estimating progression-free survival in patients with glioblastoma using routinely collected data | SpringerLink
![ANALYSIS OF SURVIVAL. The probability that an individual will survive (not die from) the cancer S URVIVAL M ORTALITY Probability of death from cancer. - ppt download ANALYSIS OF SURVIVAL. The probability that an individual will survive (not die from) the cancer S URVIVAL M ORTALITY Probability of death from cancer. - ppt download](https://images.slideplayer.com/41/11153883/slides/slide_8.jpg)
ANALYSIS OF SURVIVAL. The probability that an individual will survive (not die from) the cancer S URVIVAL M ORTALITY Probability of death from cancer. - ppt download
![JPM | Free Full-Text | Local Disease-Free Survival Rate (LSR) Application to Personalize Radiation Therapy Treatments in Breast Cancer Models JPM | Free Full-Text | Local Disease-Free Survival Rate (LSR) Application to Personalize Radiation Therapy Treatments in Breast Cancer Models](https://www.mdpi.com/jpm/jpm-10-00177/article_deploy/html/images/jpm-10-00177-g002.png)
JPM | Free Full-Text | Local Disease-Free Survival Rate (LSR) Application to Personalize Radiation Therapy Treatments in Breast Cancer Models
312: Survival After Disease Progression of Patients with Locally Advanced Bladder Cancer Previously Treated with Radical Cystect
![Clinical Characteristics, Surgical Management, and Prognostic Factors of Medullary Thyroid Carcinoma: A Retrospective, Single-Center Study - Xin Wu, Binglu Li, Chaoji Zheng, 2022 Clinical Characteristics, Surgical Management, and Prognostic Factors of Medullary Thyroid Carcinoma: A Retrospective, Single-Center Study - Xin Wu, Binglu Li, Chaoji Zheng, 2022](https://journals.sagepub.com/cms/10.1177/15330338221078435/asset/images/large/10.1177_15330338221078435-fig3.jpeg)